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T he protozoan parasite Leishmania is transmitted by the bite of an in-fected sand fly. It disproportionately affects the poorest communi-ties in endemic countries, and has an associated global mortality of 
200,000–400,000 per year1. An elimination campaign has been running in 
the Indian subcontinent (India, Nepal, Bangladesh, Bhutan and Thailand) since 
2005. Three elimination time frames currently exist; the first, ending in 2015, 
is to establish progress that has been made; the second is the elimination 
of visceral leishmaniasis as a public health problem by 2017 (committed to 
by Indian subcontinent governments and visceral leishmaniasis programme 
managers); the third, as part of the London declaration on neglected tropical 
diseases, is to eliminate visceral leishmaniasis as a public health problem by 
2020 (defined as less than 1 case of kala-azar in 10,000 people in endemic 
areas, at the block (India) and upazila (sub-district; Bangladesh) level in the 
Indian subcontinent). In this Article we use the term kala-azar to define the 
clinical disease and manifestations of the infection caused by visceral leish-
maniasis. 
Considerable progress has been made towards the target of less than 
1 case in 10,000 by implementing novel case-detection strategies, rapid di-
agnostic testing and vector control activities. At present, Nepal has achieved 
elimination for two consecutive years and Bangladesh has reached the elim-
ination targets in all upazilas (World Health Organization (WHO), personal 
communication). However, India has not yet reached these low levels and the 
latest data are more than 1 case per 10,000 people in endemic districts. This 
higher rate of incidence is thought to be due to a combination of differences 
in underlying transmission, pre-elimination campaign endemicity, health sys-
tems, diagnosis rates and the use and success of vector control programmes2. 
However, the relative contribution of these different factors has yet to be 
quantified and will be a crucial determinant of the success of the expansion 
of control programmes. 
The case-defining conditions for kala-azar in the context of the elimina-
tion programme in the Indian subcontinent are prolonged fever of more than 
2 weeks, splenomegaly and a positive rK39 test. The rK39 test is an anti-
body-based detection, immunochromatographic test that has been shown to 
have high sensitivity (around 97%) when combined with clinical symptoms3 
(Table 1). There is, however, an inherent delay in receiving treatment because 
clinical definition of a suspect case of kala-azar requires at least 2 weeks of fe-
ver. This definition is used partly because of the low specificity of the rK39 test 
to identify infection rather than exposure, and to differentiate kala-azar from 
other fever-causing aetiologies. For the control of kala-azar, it has been pro-
posed that a diagnostic test that detects active infection rather than the im-
mune response to infection could be used4. Testing earlier could identify more 
patients and interrupt transmission by early treatment. However, the speci-
ficity of such a test would have to be high to avoid false positives, as many of 
the patients tested will present with non-specific symptoms. Consequently, 
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Countries in the Indian subcontinent  have committed to reducing the incidence of kala-azar, a clinical manifestation of visceral 
leishmaniasis, to below 1 in 10,000 by 2020. We address the role of timing of use and accuracy of diagnostics in kala-azar control 
and elimination. We use empirical data on health-seeking behaviour and health-system performance from the Indian state of 
Bihar, Bangladesh and Nepal to parameterize a mathematical model. Diagnosis of cases is key to case management, control and 
surveillance. Treatment of cases prevents onward transmission, and we show that the differences in time to diagnosis in these 
three settings explain the observed differences in incidence. Shortening the time from health-care seeking to diagnosis is likely 
to lead to dramatic reductions in incidence in Bihar, bringing the incidence down to the levels seen in Bangladesh and Nepal. 
The results emphasize the importance of maintaining population and health-system awareness, particularly as transmission and 
disease incidence decline. We explore the possibility of diagnosing patients before the onset of clinical kala-azar (before 14 days 
fever), and show that this could have a marked impact on incidence, even for a moderately sensitive test. However, limited spec-
ificity (that results in false positives) is a major barrier to such a strategy. Diagnostic tests of high specificity used at an early stage 
of active infection, even if sensitivity is only moderate, could have a key role in the control of kala-azar, and prevent its resurgence 
when paired with the passive health-care system and tests of high sensitivity, such as the test for rK39 antibody response.
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the target product profile (TPP) of a diagnostic test that could identify less 
severe or even asymptomatic cases has not yet been defined. We considered 
the effect of such an intervention and the role of the specificity.
Within villages, cases of kala-azar tend to be clustered around index 
cases, suggesting that the drivers of local epidemics are individuals with ka-
la-azar5,6. Most infected people are asymptomatic, but may still contribute to 
transmission at low levels7. Patients with post-kala-azar dermal leishmaniasis 
(PKDL) are known to harbour parasites, often in the dermal region, and are as-
sumed to be infectious to sand flies8. The relative role of people with kala-azar, 
asymptomatic individuals and people with PKDL in sustaining transmission 
has not been measured directly and is unknown6,9. Some of this uncertainty 
will hopefully be addressed in the coming years, but at present more indirect 
methods are required to understand the dynamics of transmission and con-
trol. If kala-azar cases contribute to most of transmission, then early diagnosis 
and treatment is likely to be a highly effective intervention.
Very few modelling studies have been undertaken to help disentangle the 
interactions between individual, population and system processes for visceral 
leishmaniasis. This is partly because of a lack of quantitative information on 
the natural history of the disease10. The approach we present is to use a single 
model to compare information from three different endemic areas. From this 
we can infer the rates of progression through different clinical states, largely 
based on the fact that health seeking and health care have different outcomes 
in these areas. We then extend this core health-seeking model to account for 
transmission, using a simple, parsimonious framework to investigate the im-
pact of changes in diagnosis on transmission dynamics.
We consider two interventions: reducing diagnostic delays in individuals 
who already fulfil the kala-azar definition, and introducing novel diagnostics to 
enable diagnosis of those who do not, or are yet to, fulfil the clinical definition 
of 14 days of fever and splenomegaly. We consider the dynamic consequences 
of these interventions, and highlight the potential for rebound epidemics as 
population (herd) immunity is curtailed. Finally, we consider the profile of a 
diagnostic required for diagnosis and treatment prior to full kala-azar, and em-
phasise that specificity, rather than sensitivity, is the limiting factor.
METHODS
Empirical data. The data that inform the model are from studies on self-report-
ed time from symptoms to health seeking and eventual diagnosis of kala-azar 
(Fig. 1a). In Nepal and Bihar, 92 patients with kala-azar who had experienced 
103 kala-azar episodes were interviewed. Patients waited for 30 days (95% 
confidence interval (CI) = 18–42) in Nepal before seeking health care, 3.75 
times longer than in Bihar where patients waited 8 days (95% CI = 4–12). Con-
versely, the lag time from seeking health care to receiving a kala-azar diagnosis 
was 90 days (95% CI = 68–113) in Bihar compared with 25 days (95% CI = 
13–38) in Nepal. The time span between diagnosis and treatment was short in 
both countries. In Bangladesh, a 2007 cross-sectional study in Godagari Up-
zila, Rajshahi, Bangladesh by the International Centre for Diarrhoeal Disease 
Research, of the knowledge of, attitude to, and practice surrounding kala-azar 
and its treatment by communities and health providers, also screened for ka-
la-azar by rK39 dipstick test individuals who had had fever for more than 2 
weeks. Around 5,000 households were surveyed, of these, 500 randomly se-
lected household heads were interviewed, and indicated that it took 4 days 
for people to seek medical help after onset of fever and 54 days until a correct 
diagnosis. The cumulative effect of these delays means that in Bihar patients 
are diagnosed 98 days after symptoms start, whereas in Bangladesh it is 58 
days and in Nepal it is 55 days. 
Mathematical models. We initially developed a model without transmission 
that mirrors the available data on the retrospective cohort of patients who have 
been diagnosed with kala-azar (Fig. 1b). The model includes two basic transi-
tions: progression of disease from the point of developing fever to diagnosis, and 
progression to health-seeking behaviour, giving four possible states: non-health-
seeking fever (Fn), health-seeking fever (Fh), non-health-seeking kala-azar (Kn) 
and health-seeking kala-azar (Kh). Note that we are using ‘fever’ to denote 
non-specific symptoms (the patient recognises the start of the illness that leads 
to a kala-azar diagnosis, but the symptoms would have been insufficiently spe-
cific for diagnosis of kala-azar at that time). In the model, given a passive health-
care system and the absence of better diagnostics, only individuals who are 
health seeking and have clinical kala-azar can be diagnosed. We include a single 
parameter for disease progression (transitions from F to K, duration denoted 
1/a, where a is the rate of progression), thereby assuming that kala-azar does 
not have different pathology in different countries. We include three parameters 
that are determined by the health-seeking and diagnostic patterns and are lo-
cation specific — two parameters for the onset of health seeking (Fn to Fh, and 
Kn to Kh rates, denoted b and c, respectively) and one parameter for diagnosis 
(Kh to D, denoted d). The equations are given in the Supplementary Information.
The model was parameterized to each locale. Each locale has two obser-
vations: the time from onset to health-seeking behaviour (entry into Fh or Kh), 
and the time from health seeking to diagnosis (Kh to D). These periods were 
expressed as functions of the four model parameters. Unique values of the 
parameters cannot be estimated, so we generated parameter sets of a, b, c 
and d that reproduce the observed times. We assumed that individuals with 
full kala-azar are more likely to seek health care than those with non-specific 
symptoms (c ≥ b). A grid of all possible integer values for durations in each 
Diagnostic test Sensitivity Specificity 
rK39 RDT3 97.0% (95% CI = 90.0–99.5) 90.2% (95% CI = 76.1 –97.7)
DAT21 97.1% (95% CI = 94.9–98.4) 95.7% (95% CI = 88.1–98.5)
Parasitology spleen22 >95% 100%
Parasitology bone marrow22 60–85% 100%
Antigen (KAtex)22 68–100% 98%
PCR4 92.3% (95% CI = 88.4–94.9) 63.3 (95% CI = 53.9–71.8)
CI, confidence interval; DAT, direct agglutination test; PCR, polymerase chain reaction; RDT, rapid 
diagnostic test
Table 1 | Current diagnostic tests with sensitivity and specificity data taken from 
the Indian subcontinent where possible. 
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Figure 1 | Data and model on delays in diagnosis. a, Time from onset of 
symptoms (defined as fever) to health-seeking and then diagnosis, for Bihar, 
Nepal14 and Bangladesh (D. Mondal, personal communication). b, Flow diagram 
of model. Open boxes show the behaviour model with progression post-
infection through fever and full kala-azar (KA) (vertical flow), and from non-
health-seeking to health-seeking (horizontal flow) bevaviour. The shaded boxes 
and grey arrows indicate the extra states required for the transmission model. 
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state was compared with the observed outcomes. Parameter combinations 
that reproduce the observed times were retained, thus generating locale-spe-
cific combinations of parameters that produced results consistent with the 
data. The values of the parameters within the sets were correlated. For exam-
ple, to reproduce the observed time to diagnosis, a shorter period spent health 
seeking is combined with a longer time waiting for diagnosis. Therefore, the 
parameters were retained as groups of appropriate parameters rather than 
ranges of possible values.
The model was then extended to include transmission dynamics (Fig. 1b). 
The extended model includes an incidence of infection and a latent class to 
account for delays between infection and onset of symptoms. Most latently 
infected individuals recover directly to the dormant stage without progress-
ing to symptoms leading to kala-azar11. The instantaneous rate of infection is 
calculated as the weighted sum of the force of infection from the various po-
tentially infectious states: latent, fever, kala-azar and dormant. The equations, 
including analytical solution for the basic reproduction number, R0, and equi-
librium state, are given in the Supplementary Information. The basic reproduc-
tion number, R0, is defined as the average number of onward infections caused 
by a single infectious individual in a wholly susceptible population throughout 
the infectious period of that individual. R0 is a combination of the number of 
infections generated in each infection stage, which in turn is determined by 
the duration and infectiousness of the stage. For an endemic disease such as 
visceral leishmaniasis, populations are not wholly susceptible, and the number 
of onward transmissions will be reduced by potential contacts that are already 
infected or immune.
The duration of the latent stage, relative infectiousness of different stages 
and R0 cannot be measured with current diagnostics and available epidemio-
logical data. Consequently, we chose values that are consistent with current 
understanding10, that reproduce patterns consistent with general observa-
tions12, and so that the equilibrium state of the model in the three settings 
was consistent with relative epidemiological patterns. All of the biological 
parameters were the same across all three settings, so differences between 
settings were due to the differences in health-seeking behaviour and health-
care response (see Supplementary Information).
We then used the model to examine two potential interventions. First, 
we considered the impact of reducing the time to diagnosis in Bihar to that 
estimated for Nepal and Bangladesh. Second, we examined the impact of a 
diagnostic and treatment intervention applied during the pre-kala-azar fe-
ver stage. We show results both for the average incidence at equilibrium, 
which may take many years to be reached, and for the average number of 
diagnoses over the first 5 years from introduction, to demonstrate the short-
er-term effects. The impact of a diagnostic test is determined by both the 
sensitivity and specificity of each test, and how it is applied, for example a 
single test per patient or multiple testing. We include a testing rate, τ, so that 
the average interval between tests is 1/τ, and the proportion of individuals 
correctly diagnosed before the onset of kala-azar is τ SE / (τSE + a ), where SE 
is the per-test sensitivity. To account for specificity, we assume that there is 
a background rate of 200 additional cases of fever owing to other infections 
and not related to visceral leishmaniasis, and calculate the rate at which 
false positives arise as a function of the specificity per test, SP, and the rate 
of testing. We present equilibrium results, and the numbers of true and false 
positives that are expected to arise over 5 years that follow the introduction 
of such an intervention. 
RESULTS
Estimated pathways to diagnosis. The parameter sets that are consistent with 
the data are shown in Figure 2. There are 526 unique parameter combinations 
(a, b, c, d) for Bihar, 2,320 for Nepal and 312 for Bangladesh. The time between 
fever onset and progression to clinical kala-azar is 33 days < a < 55 days. In 
Nepal, individuals develop the disease faster than they seek health care, so that 
the typical path for an individual is fever to kala-azar to health seeking to diag-
nosis, with most individuals diagnosed and treated within the first few weeks of 
symptoms. In Bihar and Bangladesh, health seeking starts much earlier, but di-
agnosis is slower so that individuals enter the health system, but then remain in 
the symptomatic state without treatment. The major difference between Nepal 
and the other two regions is that kala-azar cases in Nepal most frequently first 
present to health-care services as clinical kala-azar, whereas in Bihar and Bang-
ladesh people first present with non-specific symptoms. Consequently, in Bi-
har, patients are likely to be diagnosed and treated for more common infections 
(such as bacterial infection) owing to presentation of non-specific symptoms. 
There is a risk that treatment failure, rather than misdiagnosis, is blamed, lead-
ing to repeat treatments for the wrong diagnosis. In addition, many patients 
present to unqualified practitioners or the private health-care system, delaying 
correct diagnosis13.
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Figure 3 | Impact of diagnosis delay on transmission. Sensitivity analysis of 
the effect of different overall transmissibility, β
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infectiousness of individuals with non-specific symptoms, β
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each panel the expected equilibrium incidence (cases per 10,000 per year) is 
plotted against the basic reproduction number, R
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corresponds to one of the health-seeking, diagnosis and progression parameter 
sets for Bihar; blue are for Nepal. The points for Bangladesh are masked by those 
for Nepal. 
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Figure 2 | Expected time in each stage of the model in each setting. The 
estimated duration in each stage for the combined parameter sets from each 
locale. From left to right, F
n
, the expected time before health seeking or kala-
azar (duration of time in fever, non-health-seeking state); F
h
, time spent health-
seeking with fever before kala-azar development; K
n
, duration spent with kala-
azar before health seeking; K
h
, duration spent health seeking with kala-azar; 
total, duration spent between onset and diagnosis. Within each column, the 
localities are Bangladesh (red), Nepal (blue) and Bihar (green). Note that there 
are correlations within the parameter sets so that the total time from onset to 
diagnosis is constant (final column). The violin plots indicate the variability in 
the parameter values, and the crosses mark the mean.
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Transmission dynamics. As with all transmission models, incidence of diagno-
sis increases non-linearly with the basic reproduction number, R0, for all values 
of the transmission parameters (Fig. 3). At equilibrium, as long as individuals 
with kala-azar provide most infection to vectors, the transmission potential is 
higher in Bihar than Nepal (the average number of onward transmissions per 
infected individual, R0, will be different). Only when transmission rates are high 
(Fig. 3), and therefore the number of onward infections, R0, is also high, are the 
incidences of disease in all settings similar. At this level of transmission, the di-
agnostic differences are masked by the high infectiousness of latent, fever and 
dormant cases and variation between parameter sets and settings is obliterated. 
In reality, the transmission dynamics are not at equilibrium, and incidences are 
reducing in all locations due, at least in part, to reductions in R0. Consequently, 
differences in incidence between settings can be explained by the differences in 
diagnostic delays that are consistent with the observed durations (Fig. 2). This 
suggests that variability in health-care seeking and diagnostic delays between 
different settings, and the resulting distribution of times with non-specific and 
specific symptoms are likely to have an impact on transmission patterns, par-
ticularly if there is differential infectivity at these different stages of infection14.
Dynamic consequences of interventions. Owing to a lack of further informa-
tion, we set the relative transmission parameters to be those in the central 
panel of Figure 3 (see Table 1 for parameter values). At these values, the equi-
librium for Nepal and Bangladesh is low, and elimination has been achieved for 
some parameter sets, and the equilibrium for Bihar is between 4 and 5 cases 
per 10,000 people per year. 
We consider two interventions that shorten the period of high infectious-
ness and transmission potential. The impact of these interventions on the dy-
namics of diagnoses is similar (Fig. 4). First, we switched the delay in diagno-
sis seen in Bihar (43–63 days) to the average delay in Nepal (10 days, added to 
the 14 days of fever to become a clinical suspect; Fig. 4a). A reduction in time 
to diagnosis shows an initial large peak in cases, as the cases that are ‘waiting’ 
to be diagnosed are found. This leads to a rapid reduction in transmission, 
which then leads to a decline in incidence. For a setting with an incidence of 
5 per 10,000 people per year, elimination would be achieved with this change 
in the current model. Whether or not elimination would be achieved in reality 
depends on, among other things, the details of transmission from asympto-
matic infections and spatial heterogeneities. If diagnostic delay is returned to 
its previous length after 4 years, then there is a rebound epidemic, but this is 
much slower and occurs over several years. Note that the predicted patterns 
are similar for all the parameter sets fitted to the Bihar situation.
Second, we introduce the diagnosis and treatment of patients while they 
are health seeking with non-specific febrile symptoms, before they develop 
kala-azar (before they have passed 14 days of fever and have splenomegaly; 
Fig. 4b). The dynamic response is similar to the dynamics of reducing diagnos-
tic delays for those who have kala-azar, but without the immediate diagnos-
tic spike. The modelled intervention (30% of kala-azar cases are diagnosed 
during non-specific fever) is insufficient to eliminate infection. Consequently, 
there is an epidemic while the intervention is in place, owing to the build-up 
of individuals with increased susceptibility to infection who were previously 
protected by the reduction in transmission. If the intervention is kept in place, 
then incidence eventually returns to a low level. When the intervention is re-
moved, the second epidemic is a consequence of the increase in transmission 
owing to the longer infectious period when screening of fever cases is stopped.
In both interventions, the supply of full clinical kala-azar diagnoses is cur-
tailed, transmission is reduced and there is a reduction of population (herd) 
immunity that leads to a bounce back of cases if the intervention is stopped. 
The speed at which the subsequent epidemic occurs is dependent on the 
success of the intervention — better curtailment of transmission results in a 
longer period to the next epidemic. The slow build-up means that there will 
be no obvious link between lengthening diagnosis delay and incidence, with 
clear implications for monitoring efficiency of diagnosis and treatment. In 
particular, if this intervention were implemented, then potentially there would 
be a reduction in clinical awareness of visceral leishmaniasis, resulting in a 
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Figure 4 | The impact of interventions on transmission dynamics. a, The impact 
of reducing the time to diagnosis in Bihar to 10 days plus 14 days fever; the 
green bar indicates the duration of intervention. There is an initial increase 
in diagnoses of kala-azar (KA, black lines), which then leads to a reduction in 
underlying incidence and incidence of kala-azar. The intervention is lifted at 5 
years, leading to a resurgence of cases and a large outbreak several years later. 
The different lines are for different parameter sets. b, Alternatively, the impact of 
introducing a diagnostic for febrile cases such that 30% of cases do not progress 
to kala-azar. This increases the number of diagnoses during the fever stage 
(red line) and decreases the number diagnosed with kala-azar (blue); the total 
diagnoses are shown in black. In this case, as the intervention does not lead to 
elimination, an epidemic occurs while the intervention is in place (green bar). 
When the intervention is lifted there is a further resurgence of cases.
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infection elimination, 55% is enough for elimination as a public health problem 
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the diminishing returns — halving the total number of cases of kala-azar can be 
achieved by preventing only 25% of cases from progressing.
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lengthening of diagnostic delays. We suggest that although reducing diagno-
sis delay through special efforts is likely to be an effective means to short-term 
reduction in cases, it is, depending on the epidemiological setting (baseline 
prevalence and biting rates), unlikely to be a sustainable route to long-term 
elimination. The quantitative details depend on specific parameter values and 
model structure, but this general pattern will be observed if those with ka-
la-azar contribute most of the infection to vectors and onward transmission, 
and if there is sufficient (concomitant) immunity to kala-azar. 
Impact of sensitivity of a novel diagnostic. We also consider the consequenc-
es of differing diagnostic sensitivities for diagnosis during the non-specific 
symptom phase in terms of its impact on equilibrium and short-term incidence 
of diagnoses (Fig. 5). Increased sensitivity will result in a larger proportion of 
cases being diagnosed earlier. At equilibrium, as the proportion of cases diag-
nosed increases, the incidence of diagnosis during the fever stage increases, 
but total diagnoses fall owing to reduced transmission (Fig. 5a). Elimination 
of transmission is possible even with relatively moderate sensitivity. If most 
transmission is from kala-azar cases, then halving the numbers progressing to 
this state will halve R0. However, achieving equilibrium incidence in such mod-
els takes many decades and is mainly of theoretical interest. Consequently, we 
also consider the impact on the numbers of cases expected over the 5 years 
that follow the introduction of the intervention (Fig. 5b). Clearly, the dramatic 
fall in cases (Fig. 4b) occurs for low values of sensitivity, and over the short-
term there is little extra to be gained from diagnosing more than 25–30% of 
cases before kala-azar. 
Profile of the diagnostic. We profiled the diagnostic required for early case 
detection in terms of both sensitivity and specificity (Fig. 6). The size of the 
false-positive problem is determined by the frequency of fever cases (visceral 
leishmaniasis and non-visceral leishmaniasis) being tested for kala-azar, the 
specificity of the test and the proportion of fever cases that are due to viscer-
al leishmaniasis. We, therefore, modelled a scenario in which there is a back-
ground rate of non-visceral leishmaniasis cases that present for diagnosis, and, 
to account for the possibility of multiple testing owing to the long duration of 
the fever stage for kala-azar (a known phenomenon15), we include a frequen-
cy of testing for health-seeking kala-azar cases with fever. If each person who 
seeks health care presents once, then the proportion of true cases diagnosed is 
the sensitivity (Fig. 5). However, if people are tested at multiple consultations, 
then there are multiple opportunities for a correct, true-positive result, and a 
lack in sensitivity can be overcome by more frequent testing (Fig. 6a,b). How-
ever, as the number of testing occasions increases, so the rate at which false 
positives are found increases, and increasing specificity linearly decreases the 
false positives (Fig. 6c). Holding the test frequency constant, the average pos-
itive predictive value (proportion of positives that are true positives) is shown 
in Fig. 6d as a function of sensitivity and specificity. There are likely to be many 
hundreds to thousands of false positives for every true positive identified un-
less the diagnostic, or diagnostic combination, is more than 99% specific. This 
problem is amplified by a decreasing prevalence of true infection, as witnessed 
in any elimination setting. 
DISCUSSION
Our principal conclusion is that earlier diagnosis and prompt therapy have the 
potential to reduce ongoing transmission to elimination or near-elimination 
levels. This is indeed one of the pillars of the current elimination campaign, 
and, although this is likely to have already affected transmission in Nepal and 
Bangladesh, there is a large potential gain in Bihar, given that the diagnostic 
delays in this area are longer. We have also highlighted that curtailing trans-
mission is likely to decrease population immunity in the long-term, so that 
there is a potential for large epidemics if vigilance is not maintained and diag-
nostic delays are allowed to increase. If diagnostic delays lengthen either the 
stage of health-care seeking or the ability of the system to recognise kala-azar, 
then subsequent epidemics are predicted to have a long lead time, and will 
not be immediately recognized. We have shown that the introduction of novel 
diagnostics on non-specific fever cases (before full kala-azar) can be effective 
even if sensitivity is relatively low, but that their introduction is prevented at 
present by less than ideal specificity, given the issues of delivery, safety and 
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Figure 6 | The interaction between sensitivity and specificity. a, The equilibrium incidence of kala-azar cases as a function of the sensitivity per test and the testing 
interval. Elimination is only achieved for frequently applied tests (under 15 days), but can be achieved with relatively low sensitivity. b, As in a but the cumulative 
incidence is plotted over 5 years from the start of the intervention. This tends to reduce the importance of frequent testing for highly sensitive tests. c, The 
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(short testing interval, high sensitivity in a). d, The proportion of positives that are true-positive positive predictive values, calculated as the average over 5 years 
after introduction of testing, as a function of sensitivity and specificity. The testing interval is fixed at 14 days (people seeking health care provide an opportunity for 
testing once every 2 weeks on average), and there are 200 people with non-visceral leishmaniasis fever who are health seeking. The shape is dominated by specificity 
owing to the numerical scales of b and c.
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cost of treatments. The paucity of data available to fit more complex models 
means that our results rely as much on understanding of infectious-disease 
epidemiology as on our simple model. Nonetheless, we believe that these con-
clusions are supported by current understanding, and, if nothing else, are valid, 
strong hypotheses.
We studied two mechanisms by which earlier diagnosis could occur in high-
ly endemic settings, such as Bihar. The first is improving the health system to 
reduce delays in treatment. At present, differences in the time to diagnosis be-
tween countries are assumed to be because of differing time spent in the private 
health-care system where knowledge of kala-azar is relatively poor. Potentially, 
patients present with less-specific symptoms and enter a different diagnostic 
algorithm, and kala-azar is only suspected later. A study in Bihar using accred-
ited social health activists (community health workers in India) to identify and 
refer suspected kala-azar cases showed that the time from onset of fever to 
seeking treatment and diagnosis at peripheral health facilities could be reduced 
to 32–50 days in total16. Our modelling reinforces the observation that reducing 
the time to diagnosis is an effective intervention, but as prevalence decreases 
it will be more difficult to maintain the necessary knowledge and infrastructure 
to sustain this. Intriguingly, the efficiency of the diagnostic process may have 
a natural equilibrium, depending on the frequency of diagnosis. We have also 
shown that resurgence in cases will occur after several years if transmission is 
reduced and not halted, and that the peak of the resurgence may well be higher 
than pre-intervention. Typically, local kala-azar outbreaks occur regularly — 3 
peaks have occured in India 14–15 years apart over the past 40 years17. 
The second mechanism to reduce the time to diagnosis in highly endem-
ic areas such as Bihar is to identify active infection before kala-azar onset. 
Specificity becomes important when designing a test that targets early case 
detection (before 14 days of fever). Only a test with very high specificity will 
allow patients to be treated, given the limited range of treatments available 
(toxicity, cost, administration or adherence, depending on the treatment). 
Nonetheless, if specificity is high enough to consider treating patients before 
they have 14 days of fever and become a clinical suspect, then patients could 
be tested and treated much earlier than is possible with the current diagnos-
tic algorithm. This would eliminate a pool of patients that transmit visceral 
leishmaniasis to their local community, thereby substantially reducing future 
cases. Our analysis demonstrates that sensitivity of early testing for visceral 
leishmaniasis is not the main problem. Even a moderately sensitive test (30%) 
can have dramatic affect on kala-azar transmission alongside the current test-
ing algorithm of passive surveillance with rK39. The challenge to testing earli-
er in the course of the disease, with the intention of treating, is avoiding a large 
number of false positives. However, as prevalence decreases, the positive pre-
dictive value of all tests will fall as more patients are false positives than true 
positives, but the resultant gain in sustainable elimination (if such a test were 
to be implemented) is significant. 
Limitations of this model and data gaps
There are few well-conducted studies to describe the natural history of viscer-
al leishmaniasis, which is multifactorial18, and hence the risks for an infected 
individual to become diseased are not quantified. Owing to the localized epi-
demics that are seen surrounding index cases it is reasonable to assume that 
patients with kala-azar are the main reservoir of infection for sand flies. It is also 
thought that that those with PKDL and asymptomatic individuals or those with 
a dormant infection can also be infectious to sand flies, but the evidence base 
for this relies on anecdotal studies. Only one experimental study8 has been 
published whereby sand flies were allowed to feed on four people with PKDL. 
Of the 400 fed flies, 104 became infected. In our analysis we have assumed 
that asymptomatic individuals and those with PKDL are, on average across 
the population, considerably less infectious than symptomatic cases6,9. Should 
asymptomatic individuals be more infectious than anticipated, the relative im-
portance of kala-azar cases to R0 will decrease. This means that the period of 
infectiousness will increase, reducing the probability of elimination and neces-
sitating lower overall transmission rates to maintain the levels of incidence in 
the 1–5 cases per 10,000 people per year. If people with kala-azar are less infec-
tious than we have assumed, the impact of reduction in diagnostic delays will 
be reduced, but the effect of early, novel diagnostics will be enhanced (results 
not shown). Of course, diagnostics for asymptomatic cases and people with 
PKDL may be essential for elimination if these groups are shown to be involved 
in transmission of disease and maintain long-term infections.
Unfortunately, without more detailed data, the models we have described 
are only able to highlight the qualitative patterns, although they are robust 
across a large range of biologically plausible parameters. The health-seeking 
behaviour data are informative about ranges of parameters, including the du-
ration of non-specific symptoms, a parameter that has not been previously 
estimated. The data would be greatly improved by systematically sampling a 
population in which incidence was also estimated. 
In addition to the uncertainties on the human side of transmission, we 
also know little of sand-fly behaviour, life expectancy and range. Clearly, these 
vector dynamics will have an important role in the transmission cycle and in 
the design of effective interventions against transmission.
Diagnostics of the future
Diagnostics play a crucial part in the control and elimination of kala-azar and 
are a research priority19. We argue that one avenue to revolutionize the cur-
rent control algorithm is to develop a highly specific test of active infection 
(whether symptomatic or asymptomatic), even if limited in sensitivity. There 
is currently no suitable antigen test capable of detecting active kala-azar. The 
only commercially available product, KAtex, has challenges in utility and sub-
optimal sensitivity, although we would argue that low sensitivity should not 
necessarily be considered a barrier to implementation. Simplified molecular 
diagnostic tools that can be adapted for field situations are under develop-
ment, including loop-mediated isothermal amplification20. These tests, along 
with standard polymerase chain reaction, are able to detect circulating DNA 
in the blood of individuals who are actively infected. Studies show that molec-
ular tests are very sensitive, and although they have low specificity, it may be 
that these are infections that are below the limit of detection of the reference 
standard, and therefore in fact true positives4. Diagnostics that are able to de-
tect asymptomatic infection and PKDL may also be important, depending on 
the relative role of transmission in these groups. 
Given the uncertainty in clinical progression of kala-azar and diagnostic 
performance, there is clearly a chance that some, possibly much, of the mor-
bidity and mortality caused by Leishmania infection is being misclassified. The 
process of diagnosis of kala-azar provides both the clinical information for 
treatment, as well as the data on which surveillance is built. Consequently, it is 
inevitable that 100% of cases of kala-azar are diagnosed and treated, regard-
less of the performance of the health-care system or the health-seeking be-
haviour of the population. Ideally, surveillance would include information that 
is independent of clinical diagnosis. This is particularly needed as kala-azar 
becomes rarer, and it is likely that both clinical and patient awareness wanes. 
A diagnostic tool that enables population surveillance of infection and disease, 
independent of clinical diagnosis, is a crucial step in achieving, enforcing and 
demonstrating elimination.
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